Two anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies, alirocumab and evolocumab, have been approved for the treatment of hypercholesterolaemia in certain patients. We reviewed data from Phase 3 studies to evaluate the efficacy and safety of these antibodies.
Introduction
Despite declining rates, cardiovascular (CV) disease (CVD) remains the leading cause of mortality and morbidity in Europe [4, 5] . It is now clear that correcting elevated plasma LDL cholesterol (LDL-C) is an effective way to reduce CV risk [6, 7] .
In practice, a large proportion of patients with very high CV risk do not reach the target LDL-C level recommended in Europe (<1.8 mmol l -1 [70 mg dl -1 ]) despite receiving treatment with statins, as shown by the EUROASPIRE IV study [5, 7] . Inadequate control of LDL-C in clinical practice indicates a need for more effective treatments. It may also indicate poor adherence to treatment, which is a particular concern in patients with very high CV risk [8, 9] and in those with comorbidities such as diabetes and hypertension, who need to take multiple medications [9] . In addition, statins are not well tolerated by 10-15% of patients [10] . High LDL-C levels can be influenced by lifestyle to some extent, but are mainly due to polymorphisms at numerous genetic loci [11] [12] [13] . The highly penetrant genetic mutations affecting the LDL receptor (LDLR) and apolipoprotein B have long been known to cause familial hypercholesterolaemia [14] . In 2003, a third locus associated with this inherited condition was identified: proprotein convertase subtilisin/kexin type 9 (PCSK9) [15] . The PCSK9 protein binds to LDLRs, targeting them for lysosomal degradation; this prevents the receptors from binding LDL-C and removing it from the circulation and therefore raises serum LDL-C concentrations [16] . The use of monoclonal antibodies that target PCSK9 in order to reduce plasma LDL-C is a new approach for the treatment of hypercholesterolaemia and may help address the unmet clinical need of achieving LDL-C targets for the majority of patients with high CV risk. Two fully human anti-PCSK9 monoclonal antibodies have recently been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA): alirocumab and evolocumab [17] [18] [19] [20] . Other PCSK9 inhibitors are in development [21, 22] .
In the USA, alirocumab and evolocumab are indicated for use in adults with heterozygous familial hypercholesterolaemia (HeFH) or clinical atherosclerotic CVD, such as heart attack or stroke, who require additional LDL-C lowering [17, 18] . Alirocumab and evolocumab are both used in addition to diet and maximum tolerated statin therapy [17, 18] . Evolocumab is also approved for use in combination with other LDL-C-lowering therapies in patients with homozygous familial hypercholesterolaemia (HoFH). In Europe, alirocumab and evolocumab are approved as an adjunct to diet for use in adults with primary hypercholesterolaemia (HeFH and non-familial) or mixed dyslipidaemia who do not achieve target LDL-C with other lipid-lowering medication and in patients with statin intolerance [19, 20] . Evolocumab is also approved for use in combination with other lipid-lowering therapies in patients aged 12 years and older with HoFH [20] .
PCSK9 is predominantly synthesized in the liver and is secreted into the circulation, where it has a half-life of approximately 5 minutes [23] . The anti-PCSK9 monoclonal antibodies bind circulating PCSK9, preventing PCSK9-mediated degradation of the LDLR. In the absence of PCSK9, the number of receptors on the cell surface increases and more circulating LDL-C is removed [16] . Upon saturation of circulating PCSK9, any unbound antibody binds to PCSK9 as it is synthesized and released from the liver cells [24] . At this stage, increases in the antibody concentrations do not reduce LDL-C further but extend the duration of LDL-C lowering [19, 25, 26] . Eventually, the amount of circulating PCSK9 saturates the circulating unbound antibody and LDL-C levels return to baseline [24, 25] . Alirocumab and evolocumab have the same mechanism of action. Both antibodies are cleared more quickly in patients receiving concomitant statins [19, 20] because statins increase the production of PCSK9 [27, 28] . This elevation in PCSK9 levels is thought to result from statininduced intracellular cholesterol depletion via sterol regulatory element binding proteins, which in turn promotes transcription of PCSK9 [24, 28] . Despite this effect, the reduction in LDL-C in patients receiving the recommended dose of either antibody is similar whether or not they are receiving concomitant statins [19, 20] .
Following Phase 2 trials of alirocumab, which found a dose of 150 mg every 2 weeks (Q2W) to be more effective than a higher dose of 200 mg or 300 mg every 4 weeks (Q4W) [29, 30] , a pooled study of Phase 3 trials evaluated two regimens of alirocumab with concomitant statins: 150 mg Q2W and 75 mg Q2W with a criteria-based uptitration to 150 mg Q2W at week 12 (which led to an additional 14% LDL-C reduction) [31] . As a result of these studies, the titration regimen was recommended for all patients except those requiring LDL-C reductions of more than 60%, in whom 150 mg Q2W should be the starting dose [19] . The efficacy of alirocumab does not appear to be influenced by age, body mass index, intensity of statin treatment or baseline levels of LDL-C, HDL cholesterol (HDL-C) or triglycerides [32] . The starting dose of evolocumab for adults with primary hypercholesterolaemia or mixed dyslipidaemia is also based on clinical trial data and is either 140 mg Q2W or 420 mg Q4W; the two doses are clinically equivalent [20, [33] [34] [35] . For those with HoFH, 420 mg Q4W is recommended initially, with up-titration to 420 mg Q2W if a clinically meaningful response is not achieved after 12 weeks [20] . Pooled analyses of Phase 2 data showed that the approved dosing regimens of alirocumab [36] and evolocumab [37] were not associated with any discernible adverse event (AE) signal.
The aim of this systematic review was to assess the available data from Phase 3 studies that evaluated the efficacy and safety of anti-PCSK9 monoclonal antibodies in patients with elevated LDL-C levels.
Methods

Literature search
Embase and PubMed databases were searched to identify English-language Phase 3 studies of anti-PCSK9 antibodies in patients with elevated LDL-C, published from 1 January 2005 to 20 October 2015. We also searched abstracts books published from 16 
Inclusion and exclusion criteria
For inclusion, studies had to have enrolled patients with elevated baseline LDL-C concentrations (according to their CV risk) into a Phase 3 trial of an anti-PCSK9 antibody and reported data on LDL-C. All Phase 3 studies (including randomized controlled trials, randomized trials, non-randomized trials, single-arm studies and pooled analyses that reported Phase 3 trial data separately) were included. Reports of pooled Phase 2 and Phase 3 safety data for subgroups not covered in reports of Phase 3 studies were also included. In vitro studies, animal studies and any other preclinical studies were excluded, as were editorials, letters, case reports, commentaries, interview-based research, legal cases, newspaper articles, debates, general or independent central reviews, opinions, protocols, workshops, assay studies, cytogenetic studies, surgical studies and educational material for patients. Publications containing no unique data (for example, where the results of a clinical study were reported in multiple publications) were also excluded.
Screening and data extraction
The systematic review process complied with the 2009 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [38] . The abstracts of publications identified in the initial search were screened independently by two authors to ascertain whether they met the predefined inclusion criteria. The full texts of all publications that were deemed potentially eligible for inclusion were reviewed independently by the two authors to confirm their eligibility. Conflicts between the authors would have been resolved by a third author but this was not necessary. Data were extracted from full-text publications, where available.
Data extraction
Data on patient demographics and disease characteristics, outcomes and safety for patients receiving treatment with anti-PCSK9 antibodies, and the methodology and timings used to evaluate LDL-C levels, were extracted.
Results
Systematic literature search
Once duplicates were removed, the searches of the Embase and PubMed databases returned 979 results (Figure 1 ), 930 of which were excluded at the title/abstract screening stage. The main reasons for exclusion were papers not describing original data (409 records) or not describing data on anti-PCSK9 antibodies (246). Of the 49 records selected for full-text evaluation, 28 were excluded. The most common reason for exclusion at this stage was article type (e.g. letter or commentary). At the data extraction stage, four further records were excluded because they were found to contain data duplicating other included articles [39] [40] [41] [42] . Seventeen records fulfilled the criteria for inclusion. The congress abstract search identified 909 abstracts, 19 of which were selected for inclusion. We also identified five relevant articles that were indexed in PubMed shortly after the search was completed [43] [44] [45] [46] [47] . These were included at the data extraction stage, replacing two congress abstracts presenting the same data [48, 49] .
The 39 records that were included in the review described 12 Phase 3 studies of alirocumab and nine Phase 3 studies of evolocumab, involving more than 10 000 patients overall (Table 1) , and 15 pooled analyses of efficacy from Phase 3 studies or pooled analyses of safety from Phase 2 and Phase 3 studies. Table 2 summarizes the study populations, including CV risk at baseline. No head to head studies were conducted between alirocumab and evolocumab.
LDL-C concentrations were largely measured at week 24 in the alirocumab studies (with earlier interim measurements in some studies) but at week 12 in the evolocumab studies, with some also measuring LDL-C concentrations at weeks 10, 24 and 52. The assays and their schedules are listed in Table 3 .
The baseline characteristics of the patients enrolled in the included studies are shown in Tables 2 and 4 .
Efficacy of anti-PCSK9 antibodies
Patients with hypercholesterolaemia or mixed dyslipidaemia. The studies demonstrated that the use of anti-PCSK9 antibodies was associated with a rapid (within 1-2 weeks of treatment initiation) and persistent reduction in LDL-C as measured against the comparators (Table 5) .
The majority of studies reported efficacy according to achievement of LDL-C goal (Table 5 and Figure 2 ). Generally, rates of goal achievement were highest when anti-PCSK9 antibodies were used in combination with statins and when baseline LDL-C was low. Across the alirocumab-statin combination studies, the highest rate of LDL-C goal achievement (87%) was in the subset of patients from the OPTIONS I study, who received alirocumab with atorvastatin 20 mg [50] . The lowest rate (64%) was in the alirocumab 150 mg Q4W arm of the ODYSSEY CHOICE II study, in which one-third of patients were not receiving concomitant lipid-lowering therapy [51] . All of these alirocumab combination studies included patients with high or very high CV risk. In studies of patients receiving evolocumab in combination with statins, rates for LDL-C goal achievement were highest (98%) in the YUKAWA-2 study [44] and lowest in the GAUSS-2 study [52] . Overall, LDL-C goals were achieved by 46% of the 140 mg Q2W group and 42% of the 420 mg Q4W group of GAUSS-2; however, patients were statin-intolerant, with high LDL-C at baseline (5.0 mmol l -1 [193 mg dl -1 ]) and nearly two-thirds of patients were not receiving concomitant lipidlowering therapy at baseline [52] . The DESCARTES and GAUSS-2 trials showed that evolocumab was effective across patients with high, moderately high, moderate and low CV risk according to the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III classification [52, 53] . The highest rates for LDL-C goal achievement in DES-CARTES (90% with evolocumab plus 10 mg atorvastatin; 84% with evolocumab monotherapy) were in the groups with the lowest proportion of high-risk individuals (10% and 5%, respectively); however, over two-thirds of patients in the subgroup with the greatest proportion of high-risk patients Figure 1 PRISMA flow diagram. PCSK9, proprotein convertase subtilisin/kexin type 9; PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses Table 1 Studies selected for inclusion of review of Phase 3 data on effect of anti-PCSK9 antibodies on LDL-C levels in patients with hypercholesterolaemia (64% were high-risk in the subgroup of patients who received evolocumab plus 80 mg atorvastatin and 10 mg ezetimibe) also achieved their LDL-C goal [53] . The proportions of patients receiving monotherapy who achieved their LDL-C goal ranged from 42%, which was observed in the ODYSSEY ALTERNATIVE study of alirocumab monotherapy in patients with moderate-very high CV risk and statin intolerance to 84% in the subgroup receiving evolocumab monotherapy in DESCARTES (of whom 5% had high CV risk defined using the NCEP ATP III classification) [45, 53] . The difference in baseline LDL-C levels may have influenced this difference in outcomes: mean baseline LDL-C was 4.9 mmol l -1 (191 mg dl À1 ) in the ODYSSEY ALTERNA-TIVE study and 2.7 mmol l -1 (104 mg dl À1 ) in DESCARTES.
Four studies did not report the proportion of patients who achieved their LDL-C goal [33, 34, 47, 54, 55] . ODYSSEY CHOICE I showed that the mean reduction in LDL-C was greater than 50% [55] .
Patients with familial hypercholesterolaemia. All the multiarm studies showed a significant reduction in LDL-C with the anti-PCSK9 antibody being investigated vs. the comparator ( Table 5) .
The ODYSSEY FH studies of alirocumab in combination with statins enrolled patients with HeFH. Mean placebocorrected LDL-C reductions of 51-58% were observed, with 72-81% of patients achieving their LDL-C goal [43] . In the ODYSSEY HIGH FH study, fewer patients (41%) met LDL-C goals, probably reflecting the study inclusion requirement for patients to have severe HeFH (patients with LDL-C ≥ 4.1 mmol l -1 [160 mg dl À1 ] despite maximally tolerated statin with or without lipid-lowering therapy) [56] . In the ODYSSEY LONG TERM study of alirocumab, 17.7% of patients had HeFH [57] . Data were not reported according to the aetiology of hypercholesterolaemia, but the authors stated that the percentage change in LDL-C was similar across subgroups. Overall, the calculated decrease in LDL-C level from baseline to week 24 was 61.0% with alirocumab; 79% of patients achieved their LDL-C goal (Table 5 and Figure 2 ) [57] .
In the RUTHERFORD-2 study of evolocumab monotherapy in patients with HeFH, 68% of patients in the evolocumab 140 mg Q2W arm and 63% in the evolocumab 420 mg Q4W arm achieved their LDL-C goal (Table 5 and Figure 2 ) [58] . TESLA part B [34] and an interim subgroup analysis of TAUSSIG (itself a subgroup analysis of TESLA part B; [33, 47] ) both reported data for evolocumab in patients with HoFH (it should be noted that patients with HeFH and LDL-C ≥ 3.4 mmol l [59] , were also included in these studies but data for those patients have not been reported). HoFH is a rare disease [60] and at the time of this review, there were no Phase 3 data for alirocumab in this population. The proportion of patients achieving their LDL-C goal was not reported in either evolocumab study, and the mean LDL-C reductions were less than 50% (decrease from baseline at week 12: TESLA part B, 23.1% with evolocumab vs. 7.9% with placebo ) [97] . For the purposes of this review, we assumed that patients with HeFH had a high CV risk and those with HoFH had a very high CV risk.
Systematic review of anti-PCSK9 antibodies for hypercholesterolaemia Table 3 Assays used in studies of effect of anti-PCSK9 antibodies on LDL-C levels in patients with hypercholesterolaemia 
RUTHERFORD-2 [58]
LDL-C levels determined using Friedewald formula unless triglyceride levels ≥ 4.5 mmol l LDL-C levels determined using Friedewald formula unless triglyceride levels ≥ 4.5 mmol l 
GAUSS-2 [52]
LDL-C levels determined using Friedewald formula unless triglyceride levels > 4.5 mmol l [P < 0.0001]; TAUSSIG, 21% with evolocumab; Table 5 ) [33, 34, 47] . Overall, the percentage reduction in LDL-C was similar in patients with FH and those with non-familial hypercholesterolaemia, although rates of goal achievement were lower in patients with FH.
Efficacy across subgroups
Patients with type 2 diabetes. A pooled analysis of five placebo-controlled Phase 3 alirocumab studies (ODYSSEY FH I and FH II, COMBO I, HIGH FH and LONG TERM) found that in patients with type 2 diabetes who received 75 mg alirocumab (up-titration to 150 mg if required), leastsquare mean LDL-C changes from baseline to week 24 were 43.4% for those treated with alirocumab vs. 0.3% for those who received placebo (P < 0.001). In patients without type 2 diabetes, reductions were 49.8% and 5.1%, respectively (P < 0.0001). The P-value for the effect of diabetes on LDL-C reduction was 0.02. Dose increase at week 12 was more common in patients without diabetes than in those with diabetes, which could explain these results; in patients from studies in which alirocumab was given at 150 mg from the start, type 2 diabetes had no significant effect on LDL-C reduction [61] .
A pooled analysis of data from the MENDEL-2, LAPLACE-2, RUTHERFORD-2 and GAUSS-2 evolocumab studies found that mean changes in LDL-C in patients with type 2 diabetes (n = 417; 57-60% across dosing regimens) were similar to those in individuals without the disease (n = 2729; 61-62%). Goal achievement in patients with diabetes was high, with 87-88% of patients achieving LDL-C levels below 1.8 mmol l -1 (70 mg dl À1 ) [62] . A second pooled analysis of four Phase 3 trials also found that evolocumab reduced LDL-C to a similar extent in patients with and without type 2 diabetes [63] .
Other patient subgroups. A pooled analysis of data from six alirocumab studies (ODYSSEY COMBO I and II, FH I and II, HIGH FH and LONG TERM) showed that alirocumab significantly reduced LDL-C levels compared with controls, regardless of whether or not patients were also receiving high-intensity statin treatment (atorvastatin 40-80 mg) and regardless of background lipid-lowering treatment [64] . An analysis of the efficacy of alirocumab in patients with and without moderate chronic kidney disease (CKD) across ten Phase 3 trials found that, in the majority of studies, alirocumab significantly lowered LDL-C by approximately 40-70% vs. the comparator treatment. The exception was the ALTERNATIVE trial, in which there was no significant reduction in LDL-C with alirocumab vs. the control for patients with moderate CKD; however, patient numbers were small [65] .
A pooled analysis of data from ten Phase 3 trials found that alirocumab was significantly better than the control in lowering LDL-C levels, regardless of baseline triglyceride or HDL-C concentrations [66] . Similarly, a pooled analysis of data from four Phase 3 studies found that evolocumab significantly reduced LDL-C compared with the control in patients with high LDL-C at baseline (≥4. Systematic review of anti-PCSK9 antibodies for hypercholesterolaemia that evolocumab substantially reduces LDL-C regardless of baseline PCSK9 levels [68] . A pooled analysis of nine Phase 3 alirocumab studies, across which 20-65% of patients had previously experienced a myocardial infarction (MI) or ischaemic stroke, showed that there was no interaction between previous MI or stroke and LDL-C reduction [69] .
Finally, a pooled analysis of four Phase 3 studies found that evolocumab reduced LDL-C regardless of age, gender, presence of metabolic syndrome and cardiovascular risk level [63] .
Adverse events
In general, adverse event (AE) rates were similar in the active and control arms of both combination and monotherapy studies of patients with non-familial hypercholesterolaemia ( Table 6 ). The most common AEs across the alirocumab and evolocumab studies were musculoskeletal events, nasopharyngitis and upper respiratory tract infections. The patterns of these AEs in the alirocumab studies were mixed, with just three reporting increased rates of nasopharyngitis with alirocumab vs. control (ODYSSEY MONO, ODYSSEY COMBO I and ODYSSEY CHOICE II; the biggest across-arm difference was reported in ODYSSEY MONO: 23.1% with alirocumab vs. 15.7% with control) [40, 51, 70] . An increase in musculoskeletal events was only reported in ODYSSEY CHOICE II (24.1-28.7% vs. 20.7% [51] ) and there was no clear signal that upper respiratory tract infection was more common with alirocumab than with controls.
The distribution of AEs in the evolocumab studies also varied across studies. A higher percentage of patients experienced musculoskeletal events, nasopharyngitis and upper respiratory tract infections in the evolocumab arms than in the control arms in the DESCARTES, RUTHERFORD-2 and TESLA part B studies; the biggest difference in incidence of nasopharyngitis and musculoskeletal events were in RUTHERFORD-2 (9% vs. 5% and 5% vs. 1%, respectively), while in both DESCARTES and TESLA part B, 9% of patients in the evolocumab arms experienced upper respiratory tract infections, vs. 6% in the control arms [34, 53, 58] . However, in the other comparator studies in which these AEs were reported (MENDEL, LAPLACE, GAUSS-2 and YUKAWA-2), there were either no discernible differences in the frequencies of events across active and control arms, or higher incidences in the control arms than in the evolocumab arms [44, 52, 71, 72] . In several alirocumab studies, injection site reactions were more common in the active arms than in the comparator arms, with the largest incidences seen in ODYSSEY CHOICE I (incidences with alirocumab, 5.4-18.5% across arms vs. control, 5.7-8.3%) and ODYSSEY CHOICE II (alirocumab, 3.5 and 13.8% in the 75 mg Q2W and 150 mg Q4W arms, respectively, vs. control, 0%) [51, 55] . However, in ODYSSEY MONO, injection site reactions were less frequent in the alirocumab arm compared with the control (2% vs. 4%) and, in OPTIONS I, rates were similar across arms (2-3%) [40, 50] . Across the evolocumab studies, the incidences of injection site reactions were similar in the active and control arms.
Alirocumab studies in patients with familial hypercholesterolaemia also reported similar rates of AEs in the alirocumab and placebo arms [43, 56] . However, a pooled analysis of OD-YSSEY studies (FH I and II, HIGH FH and LONG TERM [HeFH population]) found that injection-site reactions were more common in the alirocumab arm than in the placebo arm (5.9% and 4.2%, respectively) [73] . In RUTHERFORD-2 (which included only patients with HeFH), the incidences Systematic review of anti-PCSK9 antibodies for hypercholesterolaemia of AEs were 55 and 57% in the evolocumab arms and 43 and 55% in the placebo arms (Table 6 ) [58] .
In the TESLA part B study of patients with the rare genetic disease HoFH, the incidence of AEs was 36% in the evolocumab arm and 63% in the placebo arm (Table 6 ) [34] .
Serious adverse events, cardiac events, mortality and treatment discontinuation. Serious AEs were rare in all studies ( Table 6 ). The highest reported incidence of serious AEs was in ODYSSEY COMBO II and ODYSSEY LONG TERM (alirocumab 19%; ezetimibe 18%, placebo 20%) [57, 74] . In ODYSSEY LONG TERM, the authors noted that the serious AEs included allergic and neurologic AEs; however, numbers were small, with 0.5% and 0.4% of patients in the alirocumab and control arms, respectively, experiencing serious allergic AEs and 0.3% of patients in either arm experiencing serious neurologic AEs. No further details on serious AEs were given for ODYSSEY COMBO II. Few details of serious AEs were given in the evolocumab studies, apart from in DESCARTES. Of the 33 patients (5.5%) experiencing serious AEs in the evolocumab arm, only five AEs were experienced by more than one patient: angina pectoris, palpitations, ventricular extrasystoles, positional vertigo, back pain and pulmonary embolism (all two patients each; angina pectoris and pulmonary embolism also occurred in two patients and one patient, respectively, in the control arm) [53] .
Major cardiac AEs were rare: the lowest reported incidence (0%) was seen in the control arms of OPTIONS I [50] and RUTHERFORD-2 [58] , the alirocumab arm of OPTIONS II [46] and the evolocumab arm of YUKAWA-2 [44] , and the highest was 5.1% in the placebo arm of ODYSSEY LONG TERM [57] (Table 6 ). Treatment discontinuations because of AEs were similarly rare (Table 6 ): the lowest rate was observed in YUKAWA-2 (evolocumab 0%; placebo 0.5%) and the highest in ODYSSEY ALTERNATIVE (alirocumab 18%; control groups 25%) [44, 45] . The rates of treatment-emergent AEs (TEAEs) leading to death were low in all studies; the highest incidences were reported in the control arm of OP-TIONS I and the placebo arm of ODYSSEY COMBO I (2.0% and 2.8%, respectively) [50, 70] .
Patient subgroups. Pooled analyses of Phase 3 studies have found that there are no differences in the incidence of AEs in patients with diabetes vs. those without for evolocumab [62] . Similar results were seen in the alirocumab ODYSSEY LONG TERM study [75] and in a pooled analysis of alirocumab [61] , although patients with diabetes appeared less likely to experience injection-site reactions than those without. Pooled analyses of Phase 3 alirocumab studies have also found that AE incidence is not impacted by baseline triglyceride or HDL-C concentrations [66] , by whether or not patients had previously had an MI or stroke [69] , or by the presence or absence of CKD (although numerically higher treatment discontinuations were seen in patients with moderate CKD than in those without) [65] .
Pooled safety data for patient subgroups from Phase 3 and Phase 2 studies show that the AE profile of evolocumab does not vary according to body weight [76] and that there are no noticeable differences in AE profiles when comparing patients aged 65 and older with those aged 75 and older [77] .
Pooled Phase 2/3 analyses for alirocumab and evolocumab have shown that AEs are similar regardless of whether or not patients achieved very low LDL-C levels (<0. 65 [78, 79] . A pooled analysis of patients with statin intolerance from Phase 2 and Phase 3 studies of evolocumab found that safety signals in this subgroup were similar to those seen in previous analyses in broader populations [80] .
Anti-drug antibody production
Anti-drug antibody assessment was reported in six alirocumab and five evolocumab studies (Table 6 ). Pre-existing immunoreactivity to alirocumab was evident in 0.7-3.2% of patients in the ODYSSEY COMBO I and OPTIONS I studies [50, 70] . In ODYSSEY COMBO I, 6.6% of patients had a treatmentemergent positive response (i.e. developed antibodies to alirocumab following treatment) in the anti-alirocumab antibody assay; however, in more than half of these patients, the antibodies were transient despite continued treatment with alirocumab. Four of the patients developed neutralizing antibodies, but these were transient and resolved within 24 weeks [70] . In OPTIONS I, anti-drug antibody development was observed in five patients in the pooled alirocumab add-on group, three of whom had persistent antibody responses and one of whom developed neutralizing antibodies [50] . In OPTIONS II, treatment-emergent antibody development occurred in two patients; in one the response was transient and in the other it was indeterminate (i.e. it was only detected at the final sampling point); the antibodies did not appear to affect LDL-C lowering [46] . In the alirocumab arms of the ODYSSEY FH studies, 6-9% of patients developed anti-drug antibodies and 0.6% developed neutralizing antibodies [43] . In ODYSSEY MONO, six patients in the alirocumab arm (12%) developed anti-drug antibodies, five of whom had a persistent response; however, neutralizing antibodies that could affect the pharmacokinetics, efficacy or safety of alirocumab were not detected [40] . Treatmentemergent anti-drug antibodies were not detected in patients in the evolocumab arms of DESCARTES, RUTHERFORD-2 or TESLA part B [34, 53, 58] . In YUKAWA-2 one patient developed an anti-evolocumab antibody, and in LAPLACE-2 three patients in the evolocumab group tested positive for antidrug antibodies before study drug administration, one of whom had detectable anti-drug antibodies at the end of the study; neutralizing antibodies were not detected in any patient [44, 72] .
Discussion
The studies included in our systematic review show that the anti-PCSK9 monoclonal antibodies alirocumab and evolocumab are well tolerated and effective in lowering LDL-C, thereby helping patients with hypercholesterolaemia or mixed dyslipidaemia to achieve LDL-C goals. Both alirocumab and evolocumab have been demonstrated to reduce LDL-C goals across a broad patient population that encompassed a wide range of CV risk levels, and various comorbidities such as diabetes and CKD. We also noted an apparent inverse relationship between baseline LDL-C and goal achievement, suggesting that these agents have a consistent effect that is independent of baseline LDL-C levels. Statin intolerance may influence goal achievement, with the ODYS-SEY ALTERNATIVE and GAUSS-2 studies of patients with intolerance to statins reporting lower levels of goal achievement than other studies, but the data are still encouraging given the very high baseline LDL-C concentrations in patients enrolled in these studies. For both alirocumab and evolocumab, rates of AEs, serious AEs and major cardiovascular AEs were similar to those in the respective control arms. The incidence of AEs was lower when alirocumab was used as a monotherapy than when it was used in combination with statins, which could reflect differences in the patient baseline characteristics: patients in the monotherapy study had a lower CV risk level than patients in the combination studies and would be expected to be receiving fewer concomitant medicines. In contrast to alirocumab, there was no discernible pattern in AE incidence according to whether evolocumab was used as a monotherapy or in combination with statins.
Treatment-emergent anti-drug antibodies were also rare, but were reported in five alirocumab studies [40, 43, 46, 50, 70, 81] . The highest incidence of treatment-emergent antibodies was reported in the alirocumab arm of the ODYSSEY MONO study (12%). An immune signal following alirocumab administration is also noted in the summary of product characteristics, which states that, in the Phase 3 programme, allergic reactions were more common in the alirocumab groups than in the control groups (8% vs. 7%, respectively) [19] . A pooled safety analysis of nine placebo-controlled Phase 2 and Phase 3 studies also found that the incidence of local injection-site reactions was higher with alirocumab than with placebo (7% vs. 5%), even though the incidence of AEs was generally similar across the alirocumab and placebo study arms [42] .
In the evolocumab studies that investigated the presence of such antibodies, neutralizing treatment-emergent antidrug antibodies were not detected, and treatment-emergent binding antibodies were reported in just one patient (in the evolocumab arm of YUKAWA-2) [44] . The anti-drug antibody assays used were sensitive; several studies detected drug binding antibodies in patients who had not yet received evolocumab [34, 53, 72] . It should be noted, however, that different assays were used across the trials.
Overall efficacy and safety are being further evaluated for all anti-PCSK9 antibodies in ongoing long-term Phase 3 studies. A combined analysis of two randomized open-label extension studies (OSLER-1 and -2) involving 4465 patients who completed one of 12 Phase 2 or 3 evolocumab studies (and consented to participate in an extension study with an initial re-randomization after completion of the parent study) provides further relevant data that were not included in the safety section of our systematic review because it did not fulfil our inclusion criteria of including data for a patient subgroup not reported elsewhere [54] . This analysis also reported that no treatment-emergent neutralizing anti-drug antibodies were detected. Data on neurocognitive events will be of particular interest; OSLER-1 and -2 reported that although overall rates of AEs were similar in the active and control study arms, patients who received evolocumab were more likely to experience neurocognitive events (0.9% vs. 0.3% in the control arm) [54] . Similar data were seen for alirocumab in the ODYSSEY LONG TERM study (1.2% vs. 0.5% in the control arm) [57] . The effect of anti-PCSK9 antibodies on cognitive function is being investigated with a validated instrument (Cambridge Neuropsychological Test Automated Battery) in the evolocumab EBBINGHAUS trial (NCT02207634), a sub-analysis of a group of patients enrolled in the ongoing FOURIER study (NCT01764633 [82] ), and will be monitored in other ongoing Phase 3 studies, such as the alirocumab ODYSSEY OUTCOMES study (NCT01663402).
The meta-analysis by Lipinksi et al. examined the effect of anti-PCSK9 antibodies on lipids, but grouped data for alirocumab and evolocumab and did not examine the effects of these agents in different patient subgroups [83] . Other meta-analyses and literature reviews have used CV events as efficacy/safety endpoints to compare studies, but data are currently very limited [84] [85] [86] [87] . In contrast, because LDL-C reduction was the primary endpoint of the Phase 3 studies described here, the studies were statistically powered to assess the true efficacy of anti-PCSK9 antibodies regarding LDL-C lowering. Since completion of our systematic review, a meta-analysis of randomized clinical trials investigating the efficacy of evolocumab in patients with or without type 2 diabetes has been published [88] . The analysis found that the LDL-C-lowering effect of evolocumab was consistent in patients with and without type 2 diabetes. Outcomes data in this and other patient subgroups are awaited with interest.
Given that high LDL-C is recognized as a major risk factor for CVD [5, 89] , we would expect the significant reductions in LDL-C seen in these trials to translate into a reduction in CV events. ODYSSEY LONG TERM, which had the longest follow-up of the alirocumab studies included in this review, reported promising data on major CV events, with significantly fewer events in the alirocumab group than in the placebo group (1.7% vs. 3.3%; P = 0.02) [57] . A combined prespecified exploratory analysis of OSLER-1 and -2 found that the rate of CV events at 1 year was significantly reduced with evolocumab compared with standard therapy (0.47% vs. 2.2%; P = 0.003) [54] . Results from ongoing Phase 3 studies on CV outcomes, such as the alirocumab ODYSSEY OUT-COMES study, the evolocumab FOURIER study and the bococizumab SPIRE studies, are eagerly awaited [82, [90] [91] [92] .
The results from this analysis should be interpreted in the context of the study limitations. First, cross-trial comparisons should be made with caution because of the different methodologies used. For example, LDL-C was measured at different time points after drug administration. The parameters used to define CV risk also differed across the trials, with some using the SCORE system (which estimates CV mortality risk using a combination of age, sex, blood pressure, smoking status and total cholesterol [93] ) and some using the NCEP ATP III classification (which defines high and very high CV risk as elevated LDL-C in combination with other risk factors [94] ); one study used the Framingham coronary heart disease score [95] . Methodological differences among studies may be overcome to some extent by analysing the data according to patient group, because the standard of care within each group should be consistent. However, the baseline demographics of patients enrolled in the studies often varied considerably.
Even when comparing studies using the same agents, caution is required; indeed, whereas most of the alirocumab studies used a starting dose of 75 mg Q2W, increasing to 150 mg Q2W only if the response at week 8 was insufficient, the ODYSSEY LONG TERM study had a starting dose of 150 mg Q2W. Secondly, when interpreting LDL-C data, it is important to note that the Friedewald formula underestimates LDL-C at low concentrations and so its use may overestimate the effect of anti-PCSK9 antibodies [96] . Most of the included alirocumab studies used ultracentrifugation techniques if triglyceride concentrations exceeded 10.3 mmol l -1 (912 mg dl À1 ). Most evolocumab studies, however, also used ultracentrifugation if LDL-C concentrations were less than 1.0 mmol l -1
(39 mg dl À1 ), as well as if patients had high triglyceride levels.
Lastly, by limiting inclusion to published Phase 3 studies to ensure that only robust data were analysed, this review has analysed data for only two anti-PCSK9 antibodies.
Conclusions
This systematic literature review provides a detailed overview of all available published Phase 3 data, in addition to pooled Phase 2/3 data for patient subgroups, for alirocumab and evolocumab, the two fully human anti-PCSK9 monoclonal antibodies currently approved by the FDA and EMA. These drugs are being investigated further in two large study programmes, PROFICIO and ODYSSEY, respectively. Using anti-PCSK9 antibodies as 'add-on' therapy to statins or ezetimibe, or as monotherapy for patients unable to tolerate statins, will allow more patients to achieve their LDL-C goal, with few AEs or treatment discontinuations. Clinical trials to investigate the effect of anti-PCSK9 antibodies on CV events, and therefore their relevance in clinical practice, are currently underway, with results expected later this year.
